Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.4%. By the end of trading, Biogen Idec fell $4.54 (-2.1%) to $212.35 on light volume. Throughout the day, 1,022,086 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,484,500 shares. The stock ranged in price between $212.01-$217.10 after having opened the day at $214.75 as compared to the previous trading day's close of $216.89. Other companies within the Health Care sector that declined today were: Pingtan Marine Enterprise ( PME), down 82.2%, Mast Therapeutics ( MSTX), down 41.8%, Tonix Pharmaceuticals ( TNXP), down 30.2% and Dendreon ( DNDN), down 26.1%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.8 billion and is part of the drugs industry. Shares are up 48.8% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, NPS Pharmaceuticals ( NPSP), up 25.4%, Amedisys ( AMED), up 22.4%, Air Methods ( AIRM), up 16.9% and Geron Corporation ( GERN), up 16.4% , were all gainers within the health care sector with WellCare Health Plans ( WCG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI